Thursday 18 January 2007
Micronized progesterone produces increased in-phase endometria in POF women
Source: Human Reproduction 2007; Advance online publication
Comparing the endometrial histology and endocrine profiles on day 21 of an artificial cycle in women with premature ovarian failure treated with oral dydrogesterone or vaginal micronized progesterone.
Micronized progesterone is more effective than oral dydrogesterone (DG) in creating an 'in-phase' secretory endometrium, research in women with premature ovarian failure (POF) suggests.
"Hormonal support of the luteal phase in patients undergoing oocyte retrieval and embryo transfer is routinely used," H Fatemi and team, from the Dutch-Speaking Free University Brussels in Laarbeeklaan, Belgium, explain.
To explore this issue further, they randomly assigned six women with POF to receive oral DG or progesterone in two subsequent cycles.
Examination of endometrial biopsies revealed that endometrial gland development corresponded to an early secretory phase in five of the women when they recieved DG supplements (out-phase).
However, five out of six women treated with progesterone showed endometrial tissue resembling a mid-luteal phase (in-phase).
On day 21 of the artificial cycle, women who received progesterone showed significantly different average progesterone values to those who recieved DG, at 8.6 microg/l versus 0.3 microg/l, average luteinizing values, at 12.9 IU/l versus 22.5 IU/l, and average follicle-stimulating hormone values, at 13.0 IU/l versus 23.9 IU/l.
"The present study shows that vaginal administration of micronized progesterone in women with POF results in significantly more in-phase endometria, when compared with oral DG," the team concludes.
Posted: 17 January 2007
source-
http://www.orgyn.com/en/news/2007/We...91002918055556
Micronized progesterone produces increased in-phase endometria in POF women 
